Results 51 to 60 of about 284 (126)

Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension

Expert Review of Hematology
Hypertension (HTN) significantly contributes to worldwide morbidity and mortality [Citation1,Citation2]. It impacts around 1.3 billion individuals globally, rendering it one of the most prevalent cardiovascular diseases [Citation1]. Although several classes of antihypertensive drugs have shown efficacy in managing hypertension, many patients continue ...
Sahebkar, Amirhossein, Eid, Ali H.
openaire   +3 more sources

Placental transfer of the novel endothelin-1 receptor antagonist aprocitentan

Pregnancy Hypertension
Rationale: The vasoconstrictor endothelin-1 is elevated in preeclampsia, making endothelin receptor antagonists (ERAs) a logical therapeutic strategy. Here we evaluated the placental transfer of the novel ERA aprocitentan, which has recently been approved for hypertension treatment.
Kluivers, Anna C.M., Harhangi, Madhavi S., Tan, Lunbo, van der Meeren, Lotte E., Broekhuizen, Michelle, Delahaye, Stephane, Danser, A. H.Jan   +6 more
openaire   +2 more sources

Novel pharmacological approaches to lowering blood pressure and managing hypertension

Hypertension is the leading cause of death globally, primarily due to its strong association with cardiovascular disease. The global prevalence of hypertension has surged over the past three decades, driven by rising rates of diabetes mellitus and ...
Sayer, Matthew, Webb, David J, Dhaun, Neeraj   +2 more
core   +1 more source

A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension

, 2021
D. Csonka, R. Bartolucci, A. Dosne, J. J. Perez-Ruixo, I. Poggesi, P. Magni   +5 more
core   +1 more source

Aprocitentan: An oral, once-daily antihypertensive therapy for resistant hypertension in adult patients. [PDF]

Heart Int
Valdes PO, Pickard B, Orakwue C, Ferdinand K.   +3 more
europepmc   +1 more source

Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. [PDF]

J Clin Pharmacol
Csonka D, Gargano C, Goyal N, De Meulder M, Yartsev V, Ruixo JJP.   +5 more
europepmc   +1 more source

Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension. [PDF]

J Hypertens
Schlaich MP, Weber MA, Flack JM, Danaietash P, Sassi-Sayadi M, Narkiewicz K, Wang JG.   +6 more
europepmc   +1 more source

Regulatory Experiences with the Use of Multiple Imputation for Missing Data in a Phase 3 Confirmatory Trial. [PDF]

Ther Innov Regul Sci
Sassi-Sayadi M, Verweij P, Cornelisse P.
europepmc   +1 more source

Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach. [PDF]

Curr Cardiol Rep
Manickavasagar R, Krishnan A, Azzam O, Schlaich MP.   +3 more
europepmc   +1 more source

Endothelin antagonists for hypertension: has their time finally arrived? [PDF]

Clin Sci (Lond)
Schiffrin EL.
europepmc   +1 more source